Abstract 37P
Background
The "Hallmarks of Cancer" framework is foundational for understanding common organizational principles underlying diverse cancer types. However, the absence of a consensus gene set for cancer hallmarks leads to varied biological interpretations across studies. In this work, we established a unified cancer hallmark gene set by merging data from existing mapping resources and devising a framework for gene set mining.
Methods
We searched the NCBI PubMed database for publications from which a list of cancer hallmark genes could be extracted or reconstructed. Then, we performed a cancer hallmarks enrichment analysis on a list of differentially expressed genes between normal and tumor tissues across eleven solid tumor types.
Results
Consolidating hallmark genes from seven projects, we identified 6,763 genes associated with ten cancer hallmarks. We discovered a hallmark enrichment “fingerprint” specific to each tumor type. Notably, kidney cancers displayed the most extensive hallmark enrichment, underscoring the complexity of the disease. Hallmarks linked to immune function, such as “Evading immune destruction” and “Tumor promoting inflammation” were prominently enriched in kidney and CNS cancers (p<0.0001). “Tissue invasion and metastasis” was the single most prominent hallmark in skin and pancreatic cancers (p<0.0001), known to metastasize early. "Reprogramming energy metabolism" emerged as the hallmark particularly enriched in breast, ovarian, and uterine cancers (p<0.0001), suggesting the feasibility of metabolic approaches to target these cancers. The hallmark “Genome instability” was significantly enriched in cancers frequently associated with lifestyle choices, including colon, oesophageal, and liver cancers (p<0.05), and in cervical cancers, known to be linked to HPV infection (p<0.0001). To facilitate the analysis of cancer hallmarks, we developed an online tool (www.cancerhallmarks.com) to identify cancer-associated hallmarks from novel gene sets.
Conclusions
We established a consensus list of cancer hallmark genes and delineated unique patterns of hallmark enrichment across diverse tumors. Our findings hold potential pharmacological implications and enhance the utility of the hallmark concept as an effective organizational tool.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) in Hungary. O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
Presenter: Karen-Lise Spindler
Session: Poster session 07
95P - Baseline-informed longitudinal monitoring of lung cancer by cell-free DNA methylation profiles
Presenter: Chunxia Su
Session: Poster session 07
96P - A novel strategy for single-nucleus RNA-seq of frozen PAXgene blood: A clinical alternative to single-cell RNA-seq of cryopreserved PBMCs
Presenter: Asaf Rotem
Session: Poster session 07
97P - GENIE-seq: A novel methylation sequencing method for effective and accurate identification of methylation markers from cfDNA
Presenter: Zhaoyun Ding
Session: Poster session 07
98P - Translating cancer tissue methylation to cell-free DNA methylation for minimally invasive cancer detection
Presenter: Edward Post
Session: Poster session 07
99P - Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Presenter: Kyoungmin Lee
Session: Poster session 07
100P - Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay
Presenter: Lee Schwartzberg
Session: Poster session 07
101P - Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC
Presenter: Fang Wu
Session: Poster session 07